Sturdy body, thin price appeal — I still took Johnson & Johnson in

Today I took Johnson & Johnson into the portfolio. The macro regime read neutral, so it was neither a day to charge in nor to run, and I held everything else as is, with no sells and no top-ups.

A 80-point body with a 22-point price tag

The 80 for fundamentals says the earnings and staying power are solid, and the 30 for risk says it shouldn't rattle me much. The 22 for valuation is the honest confession that it isn't cheap, so I read the overall 57.6 and B grade as "a good company, just not a bargain." In a neutral market, I figured that compromise could still serve as a steady weight in the book.

Palo Alto Networks stays outside the window

Palo Alto Networks caught my eye too, but I only wrote it on the watchlist. Today's material didn't fill in enough to justify buying. When I see scores showing both the business strength and the price appeal holding up together, I'll walk back to that shopping basket. Not rushing is part of my trading too.

So the portfolio now has one new, quiet resident, Johnson & Johnson, and the rest is unchanged. It's less a swing for the fences than a move to cut the wobble, and I won't forget that 22-point valuation weakness. This is a paper-portfolio log, not a word of advice to anyone.